Pineal region germinoma

Summary

Pineal region germinoma (MONDO:0004216) is a disease and 6 clinical trials. Top therapeutic interventions include etoposide phosphate and ifosfamide. A subtype of malignant pineal area germ cell neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 6

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	pineal region germinoma
Mondo ID	MONDO:0004216
Orphanet	91352
DOID	DOID:7428
NCIT	C8712
UMLS	C0854912
MedGen	208928
GARD	0019162
Anatomy (UBERON)	UBERON:0001905
Is cancer (heuristic)	no

Also known as: germinoma · pineal germinoma

Data availability: 1 cell line.

Disease family

This is a subtype of malignant pineal area germ cell neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › central nervous system neoplasm › central nervous system germ cell tumor › malignant pineal area germ cell neoplasm › pineal region germinoma

Related subtypes (4): pineal region yolk sac tumor, pineal region dysgerminoma, pineal region choriocarcinoma, pineal region immature teratoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 6.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	4
PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02375204	PHASE3	ACTIVE_NOT_RECRUITING	Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors
NCT06368817	PHASE2	RECRUITING	A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma
NCT04648462	Not specified	RECRUITING	Proton Therapy Research Infrastructure- ProTRAIT- Neuro-oncology
NCT05564026	Not specified	RECRUITING	Molecular Epidemiology of Pediatric Germ Cell Tumors
NCT07589361	Not specified	NOT_YET_RECRUITING	Safety and Efficacy of Vertebral Body-Sparing Craniospinal Irradiation With Proton Therapy in Pediatric Tumors
NCT01445288	Not specified	COMPLETED	Exploratory Study of Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ETOPOSIDE PHOSPHATE	4	1
IFOSFAMIDE	4	1